Omalizumab for Food Allergy Part 2: Implementation Into Practice

March 2, 2024

Omalizumab for Food Allergy Part 2: Implementation Into Practice

On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In first part of a two-part series, we will review the evidence behind the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH) study that led to this FDA indication. In Part 2, we will discuss important considerations in implementing omalizumab for food allergy in your practice.


  • Dr. Sharon Chinthrajah, MD, an associate professor at Stanford University and the Director of the Sean N Parker Center for Allergy and Asthma Research. She is a co-chair of the OUtMATCH study.
  • Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study.

Important Links:

Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25.
Robert A. Wood, MD; Alkis Togias, MD; Scott H. Sicherer, MD; Wayne G. Shreffler, MD, PhD; Edwin H. Kim, MD; Stacie M. Jones, MD; Donald Y.M. Leung, MD, PhD;  Brian P. Vickery, MD; J. Andrew Bird, MD;  Jonathan M. Spergel, MD; Ahmar Iqbal, MD, MBA; Julie Olsson, MD;  Monica Ligueros-Saylan, MD; Alkaz Uddin, PhD;  Agustin Calatroni, MS; Charmaine M.  Huckabee, MS; Nicole H. Rogers, BS; Nancy Yovetich, PhD; Jennifer Dantzer, MD; Kim Mudd, RN, MSN; Julie  Wang, MD; Marion Groetch, MS, RDN; David Pyle, MD, PhD; Corinne A. Keet, MD, PhD; Michael Kulis, PhD;  Sayantani B. Sindher, MD; Andrew Long, PhD; Amy M. Scurlock, MD;  Bruce J. Lanser, MD, MPH; Tricia Lee, MD;  Christopher Parrish, MD; Terri Brown-Whitehorn, MD; Amanda K. Rudman Spergel, MD; Maria Veri, PhD; Sanaz D. Hamrah, PharmD, MHSc; Erica Brittain, PhD; Julian Poyser, MPA, MS, FNP; Lisa M. Wheatley, MD, MPH; and R. Sharon Chinthrajah, MD.

Updated FDA label for omalizumab

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to:

Today’s speakers have the following disclosures:

  • Dr. Lee has nothing to disclose.
  • Dr. Chinthrajah has consulted for Genentech and Novartis.
  • Dr. Vickery has consulted for Genentech and Novartis.

ACAAI presents this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to the procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that may be referenced.